ad image

Fast Track Designation

1 / 1
Nektar Therapeutics
Drug Development

Nektar Therapeutics Receives Fast Track Designation for the Treatment of Moderate-to-Severe Atopic Dermatitis

Nektar Therapeutics

PR-02-25-NI-07Feb 10, 2025
Accelerated Drug Development for Acute Cardiovascular and Pulmonary Care

Accelerated Drug Development for Acute Cardiovascular and Pulmonary Care

Craig Fraser

PA822Aug 25, 2021
Rafael Pharmaceuticals, Inc.
Fast Track

Rafael Pharmaceuticals Receives FDA Fast Track Designation for CPI-613® (devimistat) for the Treatment of Pancreatic Cancer

Rafael Pharmaceuticals, Inc.

PR-M11-20-012Nov 12, 2020
1 / 1